Exclusive Summary

• Holds prestigious dual GMP certifications from US-FDA and UK-MHRA, and is already registered in the US, ensuring zero compliance risk and enabling rapid market entry.
• Serves as the first-line gold standard for treating spasticity in multiple sclerosis (over 2.8 million global patients) and spinal cord injuries, ensuring massive, indispensable, and chronic market demand.
• Combines the robust cost-efficiency of the Chinese supply chain with top-tier international quality endorsements, providing overseas distributors with a highly profitable and resilient supply edge.